<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01518998</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FAC-CT-201</org_study_id>
    <nct_id>NCT01518998</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daegu Catholic University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wonkwang University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wonju Severance Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DongGuk University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yeungnam University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cheil General Hospital and Womenâ€™s Healthcare Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Busan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soon Chun Hyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic University of Korea Saint Paul's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Kangnam Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jeju National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanyang University Seoul Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antihypertensive efficacy and safety of
      Fimasartan
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sitting Diastolic Blood Pressure</measure>
    <time_frame>8weeks from baseline visit</time_frame>
    <description>To compare the difference of Sitting Diastolic Blood Pressure at 8 weeks from baseline visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sitting Systolic Blood Pressure</measure>
    <time_frame>at 4 and 8 weeks from Baseline visit</time_frame>
    <description>To compare the difference of Sitting Systolic Blood Pressure at 4,8 weeks from baseline visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sitting Diastolic Blood Pressure</measure>
    <time_frame>4weeks from baseline visit</time_frame>
    <description>To compare the difference of Sitting Diastolic Blood Pressure at 4 weeks from baseline visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder ratio</measure>
    <time_frame>at 8weeks from baseline visit</time_frame>
    <description>To compare the ratio or responder(SiDBP&lt;90mmHg or difference of SiDBP&gt;10mmHg from baseline) at 8 weeks</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Take one double-blind capsule filled with a placebo tablet in the every morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan 60mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Take one double-blind capsule filled with of Fimasartan 60mg in the every morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan 30mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Take one double-blind capsule filled with Fimasartan 30mg in the every morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Take one double-blind capsule filled with Amlodipine 5mg in the every morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Take one double-blind capsule filled with Amlodipine 10mg in the every morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan 60mg/ Amlodipine 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 5mg in the every morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan 60mg/Amlodipine 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 10mg in the every morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan 30mg/Amlodipine 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 5mg in the every morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan 30mg/Amlodipine 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 10mg in the every morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan , Amlodipine, Placebo</intervention_name>
    <description>Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Fimasartan 60mg</arm_group_label>
    <arm_group_label>Fimasartan 30mg</arm_group_label>
    <arm_group_label>Amlodipine 5mg</arm_group_label>
    <arm_group_label>Amlodipine 10mg</arm_group_label>
    <arm_group_label>Fimasartan 60mg/ Amlodipine 5mg</arm_group_label>
    <arm_group_label>Fimasartan 60mg/Amlodipine 10mg</arm_group_label>
    <arm_group_label>Fimasartan 30mg/Amlodipine 5mg</arm_group_label>
    <arm_group_label>Fimasartan 30mg/Amlodipine 10mg</arm_group_label>
    <other_name>Kanarb</other_name>
    <other_name>Norvasc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who agreed to participate in this study and submitted the written informed
             consent

          2. Subjects aged 20 to 75 years

          3. Essential hypertension subjects who are measured more 90mmHg, less than 114mmHg of
             sitting diastolic blood pressure (SiDBP) at baseline(day 0).

          4. Subjects who considered to understand this study , be cooperative, and able to be
             followed-up whole of the study period.

        Exclusion Criteria:

          1. Severe hypertension patients; more 115mmHg of SiDBP and/or more 185 mmHg of Sitting
             systolic blood pressure (SiSBP)

          2. Patients with secondary hypertension

          3. Patients with significant investigations - abnormal renal function (Creatinine more
             1.5 times than upper limit of normal), abnormal liver function (AST, ALT more 2 times
             than upper normal), moderate fatty lever needed medication

          4. Patients with significant investigations - Hypokalemia(Less than 3.5mmol/L),
             Hyperkalemia(exceeded 5.5mmol/L)

          5. Patients with sodium ion or body fluid is depleted and not able to correct

          6. Patients with hypotension who has sign and symptom

          7. Patients with surgical and medical disease it is able to be affect to absorption,
             distribution, metabolism, excretion

          8. Patients with severe insulin dependent or uncontrolled diabetes mellitus (HbA1c &gt; 9%,
             regimen change of oral hypoglycemic agent, using insulin)

          9. Patients with severe heart disease, ischemic heart disease within 6months, peripheral
             vascular disease, Percutaneous Transluminal Coronary Angiography (PTCA), Coronary
             Artery Bypass Graft (CABG)

         10. Patients with significant ventricular tachycardia, atrial fibrillation, atrial flutter
             or other significant arrhythmia

         11. Patients with hypertrophic obstructive cardiomyopathy, severe obstructive coronary
             artery disease, aortic stenosis, hemodynamically significant aortic valve or mitral
             valve disease

         12. Patients with severe cerebrovascular disease

         13. Patients with wasting disease, autoimmune disease, connective tissue disease at
             present and/or previous.

         14. Patients with known severe or malignancy retinopathy

         15. Patients with hepatitis B or C or HIV positive reaction

         16. Patients who have a story or evidence of alcohol or drug abuse within 2years

         17. Patients who are measured the mean difference of mean blood pressure of both arm under
             SiDBP 10mmHg or SiSBP 20mmHg at screening and baseline visit

         18. Patients with history of allergic reaction to any angiotensin II antagonist

         19. Patients with any chronic inflammation disease needed to chronic inflammation therapy

         20. Patients with the medical histories of malignant tumor within 5years, except local
             basal cell carcinoma of the skin

         21. Childbearing and breast-feeding women

         22. Female who plan to become pregnancy or have a possibility of pregnancy but don't
             prevent conception with acknowledged methods

         23. Patients who took medicine within 12 weeks from screening visit or is going on the
             progress of other clinical trial

         24. Subject who are judged unsuitable to participate in this study by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Kwan Jeon, Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Boryung Pharmaceutical Co., Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2012</study_first_submitted>
  <study_first_submitted_qc>January 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2012</study_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fimasartan</keyword>
  <keyword>Amlodipine</keyword>
  <keyword>antihypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

